MODERN METHODS OF TREATING FATTY HEPATOSIS
Keywords:
PPAR agonistlari, farnesoid X retseptori (FXR), fibroblast growth factor 21 analogues,Abstract
Fatty liver disease (FLD) is a common and reversible (treatable) condition in which fat cells build up in the liver.
The disease is divided into two main types: alcoholic fatty liver disease (AFLD) and nonalcoholic fatty liver disease (NAFLD). The nonalcoholic type is often associated with obesity, type 2 diabetes, insulin resistance, and metabolic syndrome. The disease is initially asymptomatic, but over time it can lead to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and even liver cancer (hepatocellular carcinoma). Diagnosis is usually made using imaging techniques such as ultrasound, CT (computed tomography), MRI (magnetic resonance imaging), liver function tests, and in some cases, a biopsy. Current treatments focus primarily on lifestyle changes—weight loss, dietary changes, increased physical activity, and control of metabolic disorders. Drug research is ongoing, but there is no universally approved specific treatment.
Early detection and treatment are essential to prevent disease progression and improve patient quality of life and outcomes.[1]
References
The Lancet Diabetes & Endocrinology Davies, M., D'Alessio, D. 231-239. 2018
Journal of Clinical Investigation. Staels, B.123-130. 2016
Hepatology. Hanish, S. 2021-2034. 2019
Nature Medicine. Kharitonenkov, A.1443-1450. 2017
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Tojiddinov Mirzoulug‘bek

This work is licensed under a Creative Commons Attribution 4.0 International License.